Skip to main content
Top
Published in: Acta Neuropathologica Communications 1/2018

Open Access 01-12-2018 | Research

The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer’s disease in individuals with Down syndrome

Authors: Yvonne S. Davidson, Andrew Robinson, Vee P. Prasher, David M. A. Mann

Published in: Acta Neuropathologica Communications | Issue 1/2018

Login to get access

Abstract

While post mortem studies have identified the major cell types and functional systems affected in Alzheimer’s disease (AD) the initial sites and molecular characteristics of pathology are still unclear. Because individuals with Down syndrome (DS) (trisomy 21) develop the full pathological changes of AD in a predictable way by the time they reach middle to late age, a study of the brains of such persons at different ages makes an ideal ‘model system’ in which the sites of earliest onset of pathology can be detected and the subsequent progression of changes be monitored. In the present study we have examined the brains of 56 individuals with DS ranging from new-born to 76 years for the presence of amyloid and tau pathology in key cortical and subcortical regions. Amyloid pathology was found to commence in the late teens to twenties as a deposition of diffuse plaques initially within the temporal neocortex, quickly involving other neocortical regions but only reaching subcortical regions and cerebellum by the late forties. Cerebral amyloid angiopathy did not regularly commence until after 45–50 years of age. Tau pathology usually commenced after 35 years of age, initially involving not only entorhinal areas and hippocampus but also subcortical regions such as locus caeruleus (LC) and dorsal raphe nucleus (DRN). Later, tau pathology spread throughout the neocortex reaching occipital lobes in most instances by mid-50 years of age. Such a pattern of spread is consistent with that seen in typical AD. We found no evidence that tau pathology might commence within the brain in DS before amyloid deposition had occurred, but there was limited data that suggests tau pathology in LC or DRN might predate that in entorhinal areas and hippocampus or at least be coincident.
Literature
1.
go back to reference Alexander M, Petri H, Ding Y, Wandel C, Khwaja O, Foskett N (2016) Morbidity and medication in a large population of individuals with Down syndrome compared to the general population. Dev Med Child Neurol 58:246–254CrossRefPubMed Alexander M, Petri H, Ding Y, Wandel C, Khwaja O, Foskett N (2016) Morbidity and medication in a large population of individuals with Down syndrome compared to the general population. Dev Med Child Neurol 58:246–254CrossRefPubMed
2.
go back to reference Allen N, Robinson AC, Snowden S, Davidson YS, Mann DMA (2014) Patterns of cerebral amyloid angiopathy define histopathological phenotypes in Alzheimer’s disease. Neuropathol Appl Neurobiol 40:136–148CrossRefPubMed Allen N, Robinson AC, Snowden S, Davidson YS, Mann DMA (2014) Patterns of cerebral amyloid angiopathy define histopathological phenotypes in Alzheimer’s disease. Neuropathol Appl Neurobiol 40:136–148CrossRefPubMed
3.
go back to reference Behrouzi R, Liu X, Wu D, Robinson AC, Tanaguchi-Watanabe S, Rollinson S et al (2016) Pathological tau deposition in motor Neurone disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy. Acta Neuropathol Commun 4:33 Behrouzi R, Liu X, Wu D, Robinson AC, Tanaguchi-Watanabe S, Rollinson S et al (2016) Pathological tau deposition in motor Neurone disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy. Acta Neuropathol Commun 4:33
4.
go back to reference Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMed Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMed
5.
go back to reference Braak H, Braak E (1998) Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm 105:801–819CrossRefPubMed Braak H, Braak E (1998) Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm 105:801–819CrossRefPubMed
6.
go back to reference Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 12:171–181CrossRef Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 12:171–181CrossRef
7.
go back to reference Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404CrossRefPubMedPubMedCentral Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404CrossRefPubMedPubMedCentral
8.
go back to reference Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960–969CrossRefPubMed Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960–969CrossRefPubMed
9.
go back to reference Burger PC, Vogel FS (1973) The development of the pathological changes of Alzheimer’s disease and senile dementia in patients with Down’s syndrome. Am J Pathol 73:457–476PubMedPubMedCentral Burger PC, Vogel FS (1973) The development of the pathological changes of Alzheimer’s disease and senile dementia in patients with Down’s syndrome. Am J Pathol 73:457–476PubMedPubMedCentral
10.
go back to reference Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I et al (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128:755–766CrossRefPubMedPubMedCentral Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I et al (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128:755–766CrossRefPubMedPubMedCentral
11.
go back to reference Davidson YS, Raby S, Foulds PG, Robinson A, Thompson JC, Sikkink S et al (2011) TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down’s syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 122:703–713CrossRefPubMed Davidson YS, Raby S, Foulds PG, Robinson A, Thompson JC, Sikkink S et al (2011) TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down’s syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 122:703–713CrossRefPubMed
12.
go back to reference Doran E, Keator D, Head E, Phelan MJ, Kim R, Totoiu M et al (2017) Down syndrome, partial trisomy 21, and absence of Alzheimer’s disease: the role of APP. J Alzheimers Dis 56:459–470CrossRefPubMedPubMedCentral Doran E, Keator D, Head E, Phelan MJ, Kim R, Totoiu M et al (2017) Down syndrome, partial trisomy 21, and absence of Alzheimer’s disease: the role of APP. J Alzheimers Dis 56:459–470CrossRefPubMedPubMedCentral
13.
go back to reference Ellis WG, McCulloch JR, Corley CL (1974) Presenile dementia in Down’s syndrome. Ultrastructural identity with Alzheimer’s disease. Neurology 24:101–106CrossRefPubMed Ellis WG, McCulloch JR, Corley CL (1974) Presenile dementia in Down’s syndrome. Ultrastructural identity with Alzheimer’s disease. Neurology 24:101–106CrossRefPubMed
14.
go back to reference Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12:383–388CrossRefPubMed Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12:383–388CrossRefPubMed
15.
go back to reference Head E, Phelan MJ, Doran E, Kim RC, Poon WW, Schmidt FA et al (2017) Cerebrovascular pathology in Down syndrome and Alzheimer disease. Acta Neuropathol Comm 5:93CrossRef Head E, Phelan MJ, Doran E, Kim RC, Poon WW, Schmidt FA et al (2017) Cerebrovascular pathology in Down syndrome and Alzheimer disease. Acta Neuropathol Comm 5:93CrossRef
16.
go back to reference Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH (1995) Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down’s syndrome. Quantitative regional analysis and comparison with Alzheimer’s disease. Arch Neurol 52:379–391CrossRefPubMed Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH (1995) Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down’s syndrome. Quantitative regional analysis and comparison with Alzheimer’s disease. Arch Neurol 52:379–391CrossRefPubMed
17.
go back to reference Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984) Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science 225:1168–1170CrossRefPubMed Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984) Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science 225:1168–1170CrossRefPubMed
18.
go back to reference Hyman BT, West HL, Rebeck GW, Lai F, Mann DM (1995) Neuropathological changes in Down’s syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. Arch Neurol 52:373–378CrossRefPubMed Hyman BT, West HL, Rebeck GW, Lai F, Mann DM (1995) Neuropathological changes in Down’s syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. Arch Neurol 52:373–378CrossRefPubMed
19.
go back to reference Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging–Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8:1–13CrossRefPubMedPubMedCentral Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging–Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8:1–13CrossRefPubMedPubMedCentral
20.
go back to reference Iwatsubo T, Mann DMA, Odaka A, Suzuki N, Ihara Y (1995) Amyloid ß-protein (Aß) deposition: Aß42(43) precedes Aß(40) in Down’s syndrome. Ann Neurol 37:294–299CrossRefPubMed Iwatsubo T, Mann DMA, Odaka A, Suzuki N, Ihara Y (1995) Amyloid ß-protein (Aß) deposition: Aß42(43) precedes Aß(40) in Down’s syndrome. Ann Neurol 37:294–299CrossRefPubMed
21.
go back to reference Jellinger KA (1998) Alzheimer-type lesions in Huntington’s disease. J Neural Transm 105:787–799CrossRefPubMed Jellinger KA (1998) Alzheimer-type lesions in Huntington’s disease. J Neural Transm 105:787–799CrossRefPubMed
22.
go back to reference Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H et al (2016) Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol 131:87–102CrossRefPubMed Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H et al (2016) Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol 131:87–102CrossRefPubMed
23.
go back to reference Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3:16–32CrossRefPubMed Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3:16–32CrossRefPubMed
24.
go back to reference Leverenz JB, Raskind MA (1998) Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 150:296–304CrossRefPubMed Leverenz JB, Raskind MA (1998) Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 150:296–304CrossRefPubMed
25.
go back to reference Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ (1999) Antibodies to alpha-synuclein detect Lewy bodies in many Down’s syndrome brains with Alzheimer’s disease. Ann Neurol 45:353–357CrossRefPubMed Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ (1999) Antibodies to alpha-synuclein detect Lewy bodies in many Down’s syndrome brains with Alzheimer’s disease. Ann Neurol 45:353–357CrossRefPubMed
26.
go back to reference Lippa CF, Rosso AL, Stutzbach LD, Neumann M, Lee VM, Trojanowski JQ (2009) Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome. Arch Neurol 66:1483–1488CrossRefPubMedPubMedCentral Lippa CF, Rosso AL, Stutzbach LD, Neumann M, Lee VM, Trojanowski JQ (2009) Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome. Arch Neurol 66:1483–1488CrossRefPubMedPubMedCentral
27.
go back to reference Lott IT, Head E (2005) Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging 26:383–389CrossRefPubMed Lott IT, Head E (2005) Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging 26:383–389CrossRefPubMed
28.
go back to reference Mann DMA (1988) The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev 43:99–136CrossRefPubMed Mann DMA (1988) The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev 43:99–136CrossRefPubMed
29.
go back to reference Mann DMA, Esiri MM (1988) The site of the earliest lesions of Alzheimer’s disease. New Eng J Med 318:789–790CrossRefPubMed Mann DMA, Esiri MM (1988) The site of the earliest lesions of Alzheimer’s disease. New Eng J Med 318:789–790CrossRefPubMed
30.
go back to reference Mann DMA, Younis N, Jones D, Stoddart RW (1992) The time course of pathological events concerned with plaque formation in Down’s syndrome with particular reference to the involvement of microglial cells. Neurodegeneration 1:201–215 Mann DMA, Younis N, Jones D, Stoddart RW (1992) The time course of pathological events concerned with plaque formation in Down’s syndrome with particular reference to the involvement of microglial cells. Neurodegeneration 1:201–215
31.
go back to reference Mann DMA, Davidson YS, Robinson AC, Allen N, Hashimoto T, Richardson A et al (2018) Patterns and severity of vascular amyloid in Alzheimer’s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer’s disease. Acta Neuropathol. https://doi.org/10.1007/s00401-018-1866-3 Mann DMA, Davidson YS, Robinson AC, Allen N, Hashimoto T, Richardson A et al (2018) Patterns and severity of vascular amyloid in Alzheimer’s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer’s disease. Acta Neuropathol. https://​doi.​org/​10.​1007/​s00401-018-1866-3
32.
go back to reference Marcyniuk B, Mann DM, Yates PO (1986) The topography of cell loss from locus caeruleus in Alzheimer’s disease. J Neurol Sci 76:335–345CrossRefPubMed Marcyniuk B, Mann DM, Yates PO (1986) The topography of cell loss from locus caeruleus in Alzheimer’s disease. J Neurol Sci 76:335–345CrossRefPubMed
33.
go back to reference Marcyniuk B, Mann DM, Yates PO, Ravindra CR (1988) Topography of nerve cell loss from the locus caeruleus in middle aged persons with Down’s syndrome. J Neurol Sci 83:15–24CrossRefPubMed Marcyniuk B, Mann DM, Yates PO, Ravindra CR (1988) Topography of nerve cell loss from the locus caeruleus in middle aged persons with Down’s syndrome. J Neurol Sci 83:15–24CrossRefPubMed
34.
go back to reference McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J (2017) TDP-43 pathology in Alzheimer’s disease, dementia with Lewy bodies and ageing. Brain Pathol 20:472–479CrossRef McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J (2017) TDP-43 pathology in Alzheimer’s disease, dementia with Lewy bodies and ageing. Brain Pathol 20:472–479CrossRef
35.
go back to reference Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123:1–11CrossRefPubMed Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123:1–11CrossRefPubMed
36.
go back to reference Obi K, Akiyama H, Kondo H, Shimomura Y, Hasegawa M, Iwatsubo T (2008) Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies. Expl Neurol 210:409–420CrossRef Obi K, Akiyama H, Kondo H, Shimomura Y, Hasegawa M, Iwatsubo T (2008) Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies. Expl Neurol 210:409–420CrossRef
37.
go back to reference Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R et al (1996) The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer’s disease and Lewy body variant. Neurology 47:190–196CrossRefPubMed Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R et al (1996) The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer’s disease and Lewy body variant. Neurology 47:190–196CrossRefPubMed
38.
go back to reference Olson MI, Shaw CM (1969) Presenile dementia and Alzheimer’s disease in mongolism. Brain 92:147–156CrossRefPubMed Olson MI, Shaw CM (1969) Presenile dementia and Alzheimer’s disease in mongolism. Brain 92:147–156CrossRefPubMed
39.
go back to reference Planel E, Richter KE, Nolan CE, Finley JE, Liu L, Wen Y et al (2007) Anaesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci 27:3090–3097CrossRefPubMed Planel E, Richter KE, Nolan CE, Finley JE, Liu L, Wen Y et al (2007) Anaesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci 27:3090–3097CrossRefPubMed
40.
go back to reference Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC et al (1998) Molecular mapping of Alzheimer-type dementia in Down’s syndrome. Ann Neurol 43:380–383CrossRefPubMed Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC et al (1998) Molecular mapping of Alzheimer-type dementia in Down’s syndrome. Ann Neurol 43:380–383CrossRefPubMed
41.
go back to reference Prasher VP, Schupf N, Sajith SG, Zigman WB, Rees S, Patel A et al (2008) Significant effect of APOE epsilon 4 genotype on the risk of Alzheimer’s disease and mortality in persons with Down syndrome. Int J Geriatr Psychiatry 23:1134–1140CrossRefPubMedPubMedCentral Prasher VP, Schupf N, Sajith SG, Zigman WB, Rees S, Patel A et al (2008) Significant effect of APOE epsilon 4 genotype on the risk of Alzheimer’s disease and mortality in persons with Down syndrome. Int J Geriatr Psychiatry 23:1134–1140CrossRefPubMedPubMedCentral
42.
go back to reference Ropper AH, Williams RS (1980) Relationship between plaques and tangles and dementia in Down’s syndrome. Neurology 30:639–644CrossRefPubMed Ropper AH, Williams RS (1980) Relationship between plaques and tangles and dementia in Down’s syndrome. Neurology 30:639–644CrossRefPubMed
43.
go back to reference Royston MC, Mann D, Pickering-Brown S, Owen F, Perry R, Raghavan R et al (1994) Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down’s syndrome from dementia. Neuroreport 5:2583–2585CrossRefPubMed Royston MC, Mann D, Pickering-Brown S, Owen F, Perry R, Raghavan R et al (1994) Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down’s syndrome from dementia. Neuroreport 5:2583–2585CrossRefPubMed
44.
go back to reference Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L et al (1993) Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases. Lancet 342:710–711CrossRefPubMed Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L et al (1993) Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases. Lancet 342:710–711CrossRefPubMed
45.
go back to reference Shinohara M, Murray ME, Frank RD, Shinohara M, DeTure M, Yamazaki Y et al (2016) Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer’s disease. Acta Neuropathol 132:225–234CrossRefPubMedPubMedCentral Shinohara M, Murray ME, Frank RD, Shinohara M, DeTure M, Yamazaki Y et al (2016) Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer’s disease. Acta Neuropathol 132:225–234CrossRefPubMedPubMedCentral
46.
go back to reference Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800CrossRefPubMed Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800CrossRefPubMed
47.
go back to reference Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kölsch H et al (2010) Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer’s disease. Acta Neuropathol 120:169–183CrossRefPubMed Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kölsch H et al (2010) Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer’s disease. Acta Neuropathol 120:169–183CrossRefPubMed
48.
go back to reference Weller RO, Boche D, Nicoll JA (2009) Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neuropathol 118:87–102CrossRefPubMed Weller RO, Boche D, Nicoll JA (2009) Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neuropathol 118:87–102CrossRefPubMed
49.
go back to reference Wenham PR, Price WH, Blandell G (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet 337:1158–1159CrossRefPubMed Wenham PR, Price WH, Blandell G (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet 337:1158–1159CrossRefPubMed
50.
go back to reference Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol 17:278–282CrossRefPubMed Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol 17:278–282CrossRefPubMed
51.
go back to reference Zigman WB, Jenkins EC, Tycko B, Schupf N, Silverman W (2005) Mortality is associated with apolipoprotein E ε4 in non-demented adults with Down syndrome. Neurosci Lett 390:93–97CrossRefPubMed Zigman WB, Jenkins EC, Tycko B, Schupf N, Silverman W (2005) Mortality is associated with apolipoprotein E ε4 in non-demented adults with Down syndrome. Neurosci Lett 390:93–97CrossRefPubMed
Metadata
Title
The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer’s disease in individuals with Down syndrome
Authors
Yvonne S. Davidson
Andrew Robinson
Vee P. Prasher
David M. A. Mann
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Acta Neuropathologica Communications / Issue 1/2018
Electronic ISSN: 2051-5960
DOI
https://doi.org/10.1186/s40478-018-0559-4

Other articles of this Issue 1/2018

Acta Neuropathologica Communications 1/2018 Go to the issue